This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Eisai Dividend

Dividend criteriumcontroles 0/6

Belangrijke informatie

2.2%

Dividendrendement

86%

Uitbetalingsratio

Gemiddelde opbrengst industrie	1.2%
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Winst per aandeel	€93.12
Toekomstig dividendrendement	2.4%

Recente dividendupdates

Geen updates

Recent updates

Stabiliteit en groei van betalingen

Dividenden ophalen

Dividendrendement versus markt

Eisai Dividendrendement versus markt

Hoe verhoudt EII0 dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (EII0)	2.2%
Markt onderkant 25% (DE)	1.6%
Markt Top 25% (DE)	4.8%
Gemiddelde industrie (Pharmaceuticals)	1.2%
Analist prognose (EII0) (tot 3 jaar)	2.4%

This company listing is no longer active

Eisai Dividend

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente dividendupdates

Recent updates

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference

Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting

DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022

Eisai Presents New Data for Lecanemab (Ban2401) At Alzheimer's Association International Conference

Merck & Co., Inc. and Eisai Co., Ltd. Provides Update on Phase 3 LEAP-002 Trial

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend